PiperJaffray Maintains Overweight on Inovio Pharmaceuticals, Lowers Price Target to $8

PiperJaffray analyst Christopher Raymond maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $10 to $8.

Benzinga · 01/03/2020 13:53

PiperJaffray analyst Christopher Raymond maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $10 to $8.